Cellular senescence as a therapeutic target to improve renal transplantation outcome

Pharmacological Research

Volumn 130, Issue , 2018, Pages 322-330

  van Willigenburg, Hester ^a   de Keizer, Peter L J ^a,b   de Bruin, Ron W F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti senescence compounds; FOXO4 DRI; Ischemia reperfusion injury; Navitoclax; Renal transplantation; Senescence

Indexed keywords

ALVESPIMYCIN; DASATINIB; FORKHEAD BOX O4 DEXTRO RETROINVERSO PEPTIDE; FORKHEAD TRANSCRIPTION FACTOR; GELDANAMYCIN; NAVITOCLAX; QUERCETIN; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CELL AGING; DRUG TARGETING; HUMAN; INFLAMMATION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; ANIMAL; TREATMENT OUTCOME;

ANIMALS; CELLULAR SENESCENCE; HUMANS; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 85042361360     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2018.02.015     Document Type: Review

References (116)

1. Hazra, N.C., Rudisill, C., Gulliford, M.C., Determinants of health care costs in the senior elderly: age, comorbidity, impairment, or proximity to death?. Eur. J. Heal. Econ., 2017, 1–12, 10.1007/s10198-017-0926-2.
2. Kontis, V., et al. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet (Lond. Engl.) 389 (2017), 1323–1335.
3. López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell, 153, 2013.
4. Marengoni, A., et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res. Rev. 10 (2011), 430–439.
5. van Oostrom, S.H., et al. Multimorbidity of chronic diseases and health care utilization in general practice. BMC Fam. Pract., 15, 2014, 61.
6. Hill, N.R., et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One, 11, 2016, e0158765.
7. Weinstein, J.R., Anderson, S., The aging kidney: physiological changes. Adv. Chronic Kidney Dis. 17 (2010), 302–307.
8. Stevens, L.A., Viswanathan, G., Weiner, D.E., Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv. Chronic Kidney Dis. 17 (2010), 293–301.
9. Heerspink, H.L., de Zeeuw, D., Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br. J. Clin. Pharmacol 76:4 (2013), 536–550.
10. Thiruchelvam, P.T.R., Willicombe, M., Hakim, N., Taube, D., Papalois, V., Renal transplantation. BMJ, 343, 2011, d7300.
11. Agarwal, R., Defining end-stage renal disease in clinical trials: a framework for adjudication: table 1. Nephrol. Dial. Transplant. 31 (2016), 864–867.
12. Lim, W.H., et al. Outcomes of kidney transplantation from older living donors. Transplant. J. 95 (2013), 106–113.
13. Slegtenhorst, B.R., et al. Mechanisms and consequences of injury and repair in older organ transplants. Transplantation 97 (2014), 1091–1099.
14. Tasaki, M., et al. Effect of donor–recipient age difference on long-term graft survival in living kidney transplantation. Int. Urol. Nephrol. 46 (2014), 1441–1446.
15. Oberhuber, R., Ge, X., Tullius, S.G., Donor age-specific injury and immune responses. Am. J. Transplant. 12 (2012), 38–42.
16. Kurschat, C., Nierentransplantation im alter. Z. Gerontol. Geriatr. 49 (2016), 488–493.
17. Braun, H., et al. Cellular senescence limits regenerative capacity and allograft survival. J. Am. Soc. Nephrol. 23 (2012), 1467–1473.
18. Melk, A., Schmidt, B.M.W., Vongwiwatana, A., Rayner, D.C., Halloran, P.F., Increased expression of senescence-associated cell cycle inhibitor p16/INK4a in deteriorating renal transplants and diseased native kidney. Am. J. Transplant. 5 (2005), 1375–1382.
19. Hoeijmakers, J.H.J., DNA damage, aging, and cancer. N. Engl. J. Med. 361 (2009), 1475–1485.
20. Campisi, J., Robert, L., Cell senescence: role in aging and age-related diseases. Interdiscip. Interdiscip. Top. Gerontol. 39 (2014), 45–61.
21. Campisi, Aging, J., Cellular senescence, and cancer. Annu. Rev. Physiol. 75 (2013), 685–705.
22. Muñoz-Espín, D., Serrano, M., Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15 (2014), 482–496.
23. Broude, EV, et al. p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation. Oncogene 26 (2007), 6954–6958.
24. Rayess, H., Wang, M.B., Srivatsan, E.S., Cellular senescence and tumor suppressor gene p16. Int. J. Cancer 130 (2012), 1715–1725.
25. van Deursen, J.M., The role of senescent cells in ageing. Nature 509 (2014), 439–446.
26. Coppé J.-P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol., 6, 2008, e301.
27. Coppé J.-P., Desprez, P.-Y., Krtolica, A., Campisi, J., The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5 (2010), 99–118.
28. Demaria, M., et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell, 31, 2014.
29. Muñoz-Espín, D., et al. Programmed cell senescence during mammalian embryonic development. Cell 155 (2013), 1104–1118.
30. Sagiv, A., Krizhanovsky, V., Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology 141 (2013), 617–628.
31. Montecino-Rodriguez, E., Berent-Maoz, B., Dorshkind, K., Causes, consequences, and reversal of immune system aging. J. Clin. Invest. 123 (2013), 958–965.
32. Hoffmann, U., et al. NK cells of kidney transplant recipients display an activated phenotype that is influenced by immunosuppression and pathological staging. PLoS One, 10, 2015, e0132484.
33. Morteau, O., et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS One, 5, 2010, e13294.
34. Franceschi, C., Campisi, J., Chronic inflammation (Inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. Ser. A Biol. Sci. Med. Sci., 69, 2014.
35. Campisi, J., Andersen, J.K., Kapahi, P., Melov, S., Cellular senescence: a link between cancer and age-related degenerative disease?. Semin. Cancer Biol. 21 (2011), 354–359.
36. Childs, B.G., Durik, M., Baker, D.J., van Deursen, J.M., Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med., 21, 2015.
37. Sturmlechner, I., Durik, M., Sieben, C.J., Baker, D.J., van Deursen, J.M., Cellular senescence in renal ageing and disease. Nat. Rev. Nephrol. 13 (2016), 77–89.
38. Bonventre, J.V., Yang, L., Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 121 (2011), 4210–4221.
39. Mosteiro, L., et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science (80-.), 354, 2016, aaf4445.
40. de Keizer, P.L.J., The fountain of youth by targeting senescent cells?. Trends Mol. Med. 23 (2017), 6–17.
41. Salvadori, M., Rosso, G., Bertoni, E., Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment. World J. Transplant. 5 (2015), 52–67.
42. Koppelstaetter, C., et al. Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging Cell 7 (2008), 491–497.
43. McGlynn, L.M., et al. Cellular senescence in pretransplant renal biopsies predicts postoperative organ function. Aging Cell 8 (2009), 45–51.
44. Melk, A., et al. Effects of donor age and cell senescence on kidney allograft survival. Am. J. Transplant. 9 (2008), 114–123.
45. Boonstra, J., Post, J.A., Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 337 (2004), 1–13.
46. Zhang, Y., et al. A new role for oxidative stress in aging: the accelerated aging phenotype in Sod1-/-mice is correlated to increased cellular senescence. Redox Biol. 11 (2017), 30–37.
47. Hochegger, K., et al. p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 292 (2007), F762–F768.
48. Kailong, L., et al. P53-Rb signaling pathway is involved in tubular cell senescence in renal ischemia/reperfusion injury. Biocell 31 (2007), 213–223.
49. Westhoff, J.H., et al. Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension 52 (2008), 123–129.
50. Jun, J.-I., Lau, L.F., Cellular senescence controls fibrosis in wound healing. Aging (Albany NY) 2 (2010), 627–631.
51. Seikrit, C., et al. Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts. Nephrol. Dial. Transplant. 28 (2013), 889–900.
52. Boor, P., Ostendorf, T., Floege, J., PDGF and the progression of renal disease. Nephrol. Dial. Transplant. 29 (2014), i45–i54.
53. Lee, D.H., Wolstein, J.M., Pudasaini, B., Plotkin, M., INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury. AJP Renal Physiol. 302 (2012), F183–F191.
54. Megyesi, J., Andrade, L., Vieira, J.M., Safirstein, R.L., Price, P.M., Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure. Kidney Int. 60 (2001), 2164–2172.
55. Nishioka, S., et al. The cyclin-dependent kinase inhibitor p21 is essential for the beneficial effects of renal ischemic preconditioning on renal ischemia/reperfusion injury in mice. Kidney Int. 85 (2014), 871–879.
56. DiRocco, D.P., et al. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. AJP Renal Physiol. 306 (2014), F379–F388.
57. Baar, M.P., Van Willigenburg, H., de Keizer, P.L.J., Maintenance and repair of an aging life cycle. Oncotarget, 1–2, 2017, 10.18632/oncotarget.18046.
58. Requião-Moura, L.R., De, M., Durão Junior, S., Carvalho De Matos, A.C., Pacheco-Silva, A., Ischemia and reperfusion injury in renal transplantation: hemodynamic and immunological paradigms. Einstein 13 (2015), 129–135.
59. McDonald, R.B., Ramsey, J.J., Honoring Clive McCay and 75 years of calorie restriction research. J. Nutr. 140 (2010), 1205–1210.
60. Dong, D., et al. Alleviation of senescence and epithelial-mesenchymal transition in aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK/mTOR signaling. Oncotarget 8 (2017), 16109–16121.
61. Krishnamurthy, J., et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 1114 (2004), 1299–1307.
62. Lanza, I.R., et al. Chronic caloric restriction preserves mitochondrial function in senescence without increasing mitochondrial biogenesis. Cell Metab. 16 (2012), 777–788.
63. Ning, Y.-C., et al. Short-term calorie restriction protects against renal senescence of aged rats by increasing autophagic activity and reducing oxidative damage. Mech. Ageing Dev. 134 (2013), 570–579.
64. Trepanowski, J.F., Canale, R.E., Marshall, K.E., Kabir, M.M., Bloomer, R.J., Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: a summary of available findings. Nutr. J., 10, 2011, 107.
65. van Ginhoven, T.M., et al. Preoperative fasting induced protection against renal ischemia/reperfusion injury is independent of ghrelin in mice. Nutr. Res. 30 (2010), 865–869.
66. Jongbloed, F., et al. Preoperative fasting protects against renal ischemia-reperfusion injury in aged and overweight mice. PLoS One, 9, 2014, e100853.
67. Mitchell, J.R., et al. Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell 9 (2010), 40–53.
68. Shushimita, S., et al. Protection against renal ischemia–reperfusion injury through hormesis? Dietary intervention versus cold exposure. Life Sci. 144 (2016), 69–79.
69. Tomé-Carneiro, J., et al. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 19 (2013), 6064–6093.
70. An, H., He, L., Current understanding of metformin effect on the control of hyperglycemia in diabetes. J. Endocrinol. 228 (2016), R97–R106.
71. Noren Hooten, N., et al. Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence. Aging Cell 15 (2016), 572–581.
72. Wang, Z., et al. Metformin attenuated the inflammation after renal ischemia/reperfusion and suppressed apoptosis of renal tubular epithelial cell in rats. Acta Cir. Bras. 30 (2015), 617–623.
73. Arriola Apelo, S.I., Lamming Rapamycin, D.W., An InhibiTOR of aging emerges from the soil of easter island. J. Gerontol. A. Biol. Sci. Med. Sci. 71 (2016), 841–849.
74. Yamamoto, T., et al. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One, 9, 2014, e98972.
75. + binding pocket that regulates protein–protein interactions during aging. Science (80-.) 355 (2017), 1312–1317.
76. Yamamoto, T., et al. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One, 9, 2014, e98972.
77. Lasry, A., Ben-Neriah, Y., Senescence-associated inflammatory responses: aging and cancer perspectives. Trends Immunol. 36 (2015), 217–228.
78. Pribluda, A., et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24 (2013), 242–256.
79. Osorio, F.G., et al. Nuclear lamina defects cause ATM-dependent NF- B activation and link accelerated aging to a systemic inflammatory response. Genes Dev. 26 (2012), 2311–2324.
80. Xu, M., et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc. Natl. Acad. Sci. 112 (2015), E6301–E6310.
81. Xu, M., Tchkonia, T., Kirkland, J.L., Perspective Targeting the JAK/STAT pathway to fight age-related dysfunction. Pharmacol. Res. 111 (2016), 152–154.
82. Veroux, M., et al. Sirolimus in solid organ transplantation: current therapies and new frontiers. Immunotherapy 3 (2011), 1487–1497.
83. Baker, D.J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479 (2011), 232–236.
84. Baker, D.J., et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature 530 (2016), 184–189.
85. Tse, C., et al. ABT-263: a potent and orally bioavailable bcl-2 family inhibitor. Cancer Res. 68 (2008), 3421–3428.
86. Chang, J., et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22 (2015), 78–83.
87. Yosef, R., et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun., 7, 2016, 11190.
88. Gandhi, L., et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29 (2011), 909–916.
89. Conchon, M., Freitas de, C.M.B.M., Rego, M.A. do C., Braga Junior, J.W.R., Dasatinib – clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia. Rev. Bras. Hematol. Hemoter. 33 (2011), 131–139.
90. Zhu, Y., et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY) 9 (2017), 955–963.
91. Zhou, P., Sun, X., Zhang, Z., Kidney-targeted drug delivery systems. Acta Pharm. Sin. B 4 (2014), 37–42.
92. Baar, M.P., et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 169, 2017.
93. van der Horst, A., et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat. Cell Biol. 8 (2006), 1064–1073.
94. Hosaka, T., et al. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 2975–2980.
95. Martins, R., Lithgow, G.J., Link, W., Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell 15 (2016), 196–207.
96. Kruiswijk, F., Labuschagne, C.F., Vousden, K.H., p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16 (2015), 393–405.
97. Sawyer, N., Watkins, A.M., Arora, P.S., Protein domain mimics as modulators of protein–Protein interactions. Acc. Chem. Res. 50 (2017), 1313–1322.
98. Zhu, Y., et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14 (2015), 644–658.
99. Zhu, Y., et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell, 15, 2016.
100. Roos, C.M., et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15 (2016), 973–977.
101. Schafer, M.J., et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun., 8, 2017, 14532.
102. Fuhrmann-Stroissnigg, H., et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun., 8, 2017, 422.
103. Workman, P., Powers, M.V., Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer. Nat. Chem. Biol. 3 (2007), 455–457.
104. Bendell, J.C., et al. A phase 2 study of the hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors. Cancer Invest. 34 (2016), 265–270.
105. Seggewiss-Bernhardt, R., et al. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer 121 (2015), 2185–2192.
106. Socinski, M.A., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin. Cancer Rancer Res. 19 (2013), 3068–3077.
107. Ferry, D.R., et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res 2 (1996), 659–668.
108. Askari, G., Ghiasvand, R., Feizi, A., Ghanadian, S.M., Karimian, J., The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J. Res. Med. Sci. 17 (2012), 637–641.
109. Tolcher, A.W., et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 76 (2015), 1025–1032.
110. Vlahovic, G., et al. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Invest. New Drugs 32 (2014), 976–984.
111. Wilson, W.H., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11 (2010), 1149–1159.
112. Homme, J., Fertita, D., Shuman, M., van Leeuwen, T., Un-reborn again. QOTSA, 6, 2017.
113. Valentijn, F.A., Falke, L.L., Nguyen, T.Q., Goldschmeding, R., Cellular senescence in the aging and diseased kidney. J. Cell Commun. Signal., 1k14, 2017, 10.1007/s12079-017-0434-2.
114. McKay, D., Jameson, J., Kidney transplantation and the ageing immune system. Nat. Rev. Nephrol. 8 (2012), 700–708.
115. Tang, J.T., et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin. Drug Metab. Toxicol. 12 (2016), 555–565.
116. Sagiv, A., Krizhanovsky, V., Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology 14 (2013), 617–628.